Coventry and Warwickshire Area Prescribing Committee
Formulary
Formulary
10 Musculoskeletal and joint diseases
10-01-03 Sulfasalazine
| Sulfasalazine |
|
Formulary
|
Treatment of active rheumatoid arthritis |
 Sulfasalazine - shared care agreement |
|
Links
- APC SCA023: Methotrexate - shared care agreement
- Azathioprine - shared care agreement
- Ciclosporin - shared care agreement
- Gold - share care agreement
- Hydroxychloroquine - shared care agreement
- Leflunomide - shared care agreement
- NICE CG177: Osteoarthritis - care and management
- NICE CG79: Rheumatoid arthritis in adults: management
- NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199)
- NICE TA220: Psoriatic arthritis - golimumab
- NICE TA225: Rheumatoid arthritis - golimumab
- NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
- NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA375: Rheumatoid arthritis
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
- NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
- NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
- NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
- NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
- NICE TA518: Tocilizumab for treating giant cell arteritis
- Penicillamine - shared care agreement
- Sulfasalazine - shared care agreement